Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) EBT Margin (2024 - 2025)

Silence Therapeutics (SLN) has disclosed EBT Margin for 2 consecutive years, with 229144.12% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 22909422.0% to 229144.12% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 201.5% through Dec 2025, up 30418.0% year-over-year, with the annual reading at 192.84% for FY2025, 29563.0% up from the prior year.
  • EBT Margin hit 229144.12% in Q4 2025 for Silence Therapeutics, up from 13180.5% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 229144.12% in Q4 2025 to a low of 20091.55% in Q1 2025.